Introduction Capturing the patient experience during treatment is important to both regulatory authorities and to patients starting treatment. We identified the symptoms and side effects experienced by patients with advanced nonsmall-cell lung cancer during osimertinib treatment, to understand treatment expectations, satisfaction, and the level of difficulty coping with the side effects experienced during treatment. Methods Qualitative interviews (approximately 4-6 weeks after treatment initiation and again after approximately 4 months of treatment) were conducted during the phase I/II AURA clinical trial of osimertinib, a tyrosine kinase inhibitor of epidermal growth factor receptor-sensitizing and T790M resistance mutations. Results During the first interview (23 patients), the most commonly reported symptoms/side effects were coughing, itching, tiredness (each reported by 56.5% of patients), and rash (43.5%). During the second interview (21 patients), compared with the first interview, shortness of breath and diarrhea were reported by more patients (57.1 and 38.1%, respectively; both increased from 34.8%); tiredness remained predominant (42.9%); and itching (38.1%), coughing (38.1%), and rash (14.3%) were reported by fewer patients. At both interviews, the most frequently reported symptoms/side effects were also those most often rated by patients for bothersomeness and severity, and generally received mean scores in the low-to-moderate range. However, several rarely expressed symptoms/side effects (e.g., abdominal pain, frequent day time urination) received high bothersomeness ratings. At the second interview, patients were highly satisfied with osimertinib and had a low level of difficulty in coping with side effects during treatment. Conclusions These data enhance our understanding of patients' experiences of symptoms/side effects, which could increase the accuracy of the osimertinib benefit-risk assessment, guide management of adverse events, and improve the information given to patients receiving the drug.
Introduction
Accurate and reliable methods of comprehensively detecting adverse events (AEs) in clinical research are essential for understanding drug toxicity profiles and maximizing patient safety. It is standard practice to report AEs in clinical trials; typically, the Common Terminology Criteria for Adverse Events (CTCAE) is used in cancer trials. The CTCAE is a system of reporting AEs that was developed by the US National Cancer Institute (NCI) and has recently been aligned with the lexicon used in the Medical Dictionary for Medical Affairs to report AEs in industry trials [1] .
Patient reports of AEs to their clinicians may not fully reflect patient experience. This is because patients may not report their full range of symptoms in response to specific questions, thus introducing selectivity. Furthermore, the subjective statements from the patient are open to interpretation by the clinician. Under-reporting by the clinician can occur, particularly for AEs that are symptomatic and thus more subjective in nature (e.g., nausea, fatigue or dyspnea) compared with AEs with observable signs (e.g., vomiting, rash, and cough) [2] [3] [4] . Further, this reporting often does not provide information regarding the bothersomeness of the symptom to the patient. In contrast, by conducting structured patient interviews, unique and personal patient perspectives can be obtained about the full picture of the side effects experienced during treatment. This is recognized by regulatory authorities, who emphasize the importance of understanding patient experiences in establishing the benefit-risk profile of a drug [5] [6] [7] . Hence, the NCI has developed the Patient-Reported Outcome CTCAE (PRO-CTCAE), a companion to the CTCAE, which includes items in plain language that describe symptoms and have been identified as suitable for patient self-reporting [1] . The PRO-CTCAE is designed to evaluate symptomatic toxicity in patients participating in cancer clinical trials, with items focused on capturing information on the frequency and severity of symptoms during treatment and their effect on usual daily activities.
Osimertinib (AZD9291) is a potent, oral, selective, irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR)-sensitizing and T790M resistance mutations in advanced non-small-cell lung cancer (aNSCLC) that has been shown to be efficacious and tolerated as a monotherapy [8] , and to have activity in the central nervous system [9] . Most patients treated with firstline EGFR-TKI eventually develop resistance [10] [11] [12] , and the EGFR T790M mutation is found in approximately 60% of such cases [13] [14] [15] . Osimertinib has been granted conditional approval for use in patients whose tumors have the specific mutation T790M, including approval from the US Food and Drug Administration (FDA) [16] and the European Medicines Agency [15] . Trials of osimertinib are ongoing in aNSCLC, including in first-line EGFR mutation-positive patients.
Knowledge of the symptoms/side effects experienced by patients with aNSCLC while taking osimertinib can be used to inform its benefit-risk profile and provide information to patients initiating treatment with osimertinib, and could also guide AE assessment and management in future trials of similar compounds. The aim of this patient interview study was therefore to identify and document all the symptoms and side effects experienced by patients with aNSCLC at two time points during treatment with osimertinib, and to collect information from patients on their treatment expectations and satisfaction, and the level of difficulty in coping with side effects experienced during treatment.
Materials and Methods

Participants
This was a substudy of the AURA phase I/II clinical trial (ClinicalTrials.gov ID: NCT01802632). Patients were recruited at seven sites in the UK, USA, Korea, and Spain, and were at least 18 years of age with an established clinical diagnosis of EGFRm-positive aNSCLC. Specifically, patients had disease progression while on a previous continuous treatment with an EGFR-TKI, e.g., gefitinib or erlotinib, and may or may not have had additional chemotherapy regimens. Patients had a tumor that harbored an EGFRm known to be associated with EGFR-TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) and/or had experienced clinical benefit from EGFR-TKI therapy. Study coordinators at each site identified interested participants during the recruitment and enrollment procedures for the AURA clinical trial. Patients who then received the study drug in the clinical trial were invited to participate in qualitative interviews. After patients had given their informed consent to be interviewed, their contact information was communicated to the project coordinator for the qualitative interview vendor (Health Research Associates), who then scheduled a telephone interview with the patient. Institutional review board approval was obtained, and this study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements. There were no known risks to the patients. All data collected in this study were strictly confidential in accordance with local, state, and federal law.
Interviewer Training and Quality Assurance
In total, four different individuals conducted the qualitative interviews. These individuals were experienced in the interviewing techniques required for the development of PRO measures, and in conducting patient interviews across a wide range of therapeutic areas, including aNSCLC. Interviews were semi-structured and conducted in each patient's native language.
Interviewers received training specific to this study in two parts. In the first part, the interviewers reviewed the content of the Concept Elicitation Interview Guides (see the electronic supplementary material for the study interview guides used during the initial and second interviews) and discussed logistics and general flow of the questions and probes. In the second part, the interviewers rehearsed the logistics of the interview process with each other, conducting mock interviews in order to identify any problematic or sensitive issues. During the mock interviews, no problematic issues were found with the flow or content of the interview guides.
Concept Elicitation Interviews
Interviews were conducted with patients by telephone approximately 4-6 weeks after initiation of osimertinib treatment (20-240 mg daily) and again after approximately 4 months of treatment. The time points selected for the interviews were based on learnings from earlier clinical trials; the first interview was conducted when patients were expected to experience a 'peak' of AEs, whilst the second interview was conducted when AEs were expected to have stabilized/minimized and patients should have started to benefit from treatment. Interviews typically lasted about 30 min. In order to focus patients on changes related to the current study treatment, patients were asked at their first interview to describe what a typical day was like on the treatment they were on before they entered the study, and to talk about symptoms that they thought were related to their lung cancer. The interview then progressed to questions about the specific side effects experienced so far in relation to their treatment with osimertinib (e.g., 'Have you experienced any side effects related to your recent cancer treatment with AZD9291?').
Questions at the second interview were initially openended and focused mainly on the side effects experienced when taking osimertinib, before moving on to questions about satisfaction with osimertinib treatment, including what the patients' expectations and desired effects of the trial medication were, and their definition of what constitutes a successful treatment. Patients were then asked to rate their treatment satisfaction and the level of difficulty experienced with symptoms/side effects during treatment with osimertinib on a numeric rating scale (0 indicated 'not at all/none' and 10 indicated 'extremely/a great deal').
Both interviews were concluded by asking a set of more specific probing questions to cover other potential symptoms/side effects that patients had not mentioned spontaneously during the interviews. Rating exercises were used to assess how bothersome or severe patients found each symptom/side effect, using a numeric rating scale (0 indicated 'not at all' and 10 indicated 'extremely bothersome/severe').
Qualitative Analysis
In order to organize the varied patient expressions collected during the concept elicitation interviews, a coding framework was developed. This allowed the symptom/side effect concepts to be grouped by similar content for qualitative analysis. Digital audio files of the patient interviews were transcribed, translated into English when necessary and analyzed using qualitative data analysis software (Atlas.ti, version 7.0) to track the coding assignment and facilitate the concept grouping.
Patient expressions of symptoms/side effects were identified in the English transcripts and tagged by five 'coders,' who assigned appropriate concept codes to these expressions (see example in Box 1). Each transcript was randomly assigned to one of the coders, with the exception of four transcripts that were each randomly assigned to two coders to estimate inter-rater agreement. The initial draft of the coding framework was based on the study objectives and the interview guide. The framework was expanded during the coding process as new concepts arose in the transcripts.
During the initial interview, saturation of concept was used to determine whether or not additional information was still forthcoming and if the data set could be considered complete. This was evaluated by ordering the transcripts chronologically and then creating groups, each comprising five or six transcripts. After concepts appearing in the first transcript group were coded, each subsequent group was evaluated and compared with the previous group in order to identify whether any new concept codes had arisen. Saturation of concept was considered to be met when no new concepts appeared.
Results
Study Participants and Data Quality Assessments
A total of 23 patients participated in initial interviews (six from the UK, six from the USA, eight from Korea, and three from Spain). Of these patients, 21 participated in second interviews (six from the UK, five from the USA, seven from Korea, and three from Spain). One patient withdrew from the clinical trial before the 4-month treatment time point because of disease progression. Another patient declined to participate in the second interview.
Patients who participated in the first interview had a median age of 62 years (33-82 years) and 65% were female. Approximately one-third (31%) of patients were white, 39% were Asian, and 30% were of 'other' ethnicity. Supplementary online material Table 1 shows the interview participant demographics compared with those of the total patient population of the phase III (AURA 3) clinical trial [17] , the target patient group for osimertinib. The interview participants had a similar median age, age range, and sex ratio to the phase III study population. While patients of Asian race were underrepresented in the interviews because of the difficulty in participant recruitment overall, there is an overrepresentation of 'other' ethnicities, which is likely to have included a number of patients with mixed ethnic backgrounds.
High inter-rater agreement was demonstrated in the identification and assignment of concept codes. Among the four dual-coded transcripts, there was 92.0-95.5% agreement between coders in terms of the sections of text identified as concepts requiring coding, and 92.9-98.6% agreement regarding the codes assigned to the concepts identified by both coders. All 77 unique concepts occurred in the first three of the four consecutive groups of interview transcripts. No additional concepts (new information) appeared in the fourth transcript group, thus demonstrating saturation of concept and indicating the point at which further interviews were not likely to provide additional information. Furthermore, comparison of concepts between the first and second interviews showed that no new concepts arose in the second interviews (although the frequency of expression of certain symptoms changed between interviews, as is detailed later in the results).
Qualitative Analysis
Frequency of Symptoms/Side Effects Reported
at the First Interview Table 1 shows the number of expressions for each symptom/side effect at both the initial interview and the second interview, as well as the number of patients who expressed them. In total, during the initial interview, 662 expressions of symptoms/side effects were reported by 23 patients, relating to their treatment experience. The five predominant concept categories in the transcript database (from highest to lowest in terms of the combined frequency of expressed concepts within each category) were 'skin/nails,' 'respiratory,' 'pain and discomfort,' 'digestive', and 'low energy,' accounting for 83.3% of all expressed concepts. The most frequently reported concept was itching, followed by coughing, tiredness, shortness of breath, diarrhea, and rash. These were also the concepts expressed spontaneously by the most patients (especially rash, diarrhea, and tiredness) rather than in response to questions about specific symptoms/side effects (Table 2) , with the exception of body pain, which was also often spontaneously expressed.
Frequency of Symptoms/Side Effects Reported at the Second Interview
In total, 573 expressions of symptoms/side effects were reported by 21 patients during the second interview. The five concept categories that dominated the transcript database during the first interview were also dominant during the second interview. However, the order (highest to lowest) changed to 'digestive,' 'respiratory,' 'skin/nails,' 'pain and discomfort,' and 'low energy.' This change in order was mainly due to an increase in the frequency of symptoms/side effects expressed in the 'digestive' category. However, the proportion of total concepts in the transcript database accounted for by these five concept categories decreased from 83.3 to 70.0%. Although tiredness was expressed at a similar frequency during both interviews, it became the most frequently expressed symptom/side effect during the second interview because itching and coughing were expressed approximately half as often as in the first interview ( Table 1 ). The frequency of reports of shortness of breath and diarrhea increased slightly at the second interview, becoming the second and third most frequently expressed concepts, followed by itching, numbness/tingling, and coughing (all accounting for at least 4.0% of expressed concepts). Rash Only symptoms/side effects that comprised C1.5% of the total number of symptoms/side effects expressions in the transcript database for either interview are shown in this table a No individual concepts in the sleep disturbance domain comprised C1.5% of the total symptom expressions was reported less frequently during the second interview than during the first interview. Several other symptoms/ side effects (hot flushes, mouth sores, dry mouth, and difficulty swallowing) were reported at a similar frequency to rash at the second interview (range 3.0-3.5%) with increased frequency compared with the first interview (range 0.5-2.1% at first interview). The symptom/side effect concepts expressed at the highest frequencies were also spontaneously reported by the most patients (Table 2) .
Bothersomeness and Severity of Symptoms/Side Effects at the First Interview
The symptoms/side effects that were most frequently (n C 5) rated as bothersome and severe (itching, coughing, tiredness, shortness of breath, diarrhea, rash, and poor appetite) had mean scores in the low-to-moderate range (Table 2) . Of these, poor appetite and tiredness received the highest mean bothersomeness and severity scores. Rash received the next highest mean severity score, but received the lowest mean score for bothersomeness. Several symptoms/side effects (abdominal pain, body pain, and voice changes) received high bothersomeness and severity scores (range 7.5-10), but were rated by only one or two patients each. Headache (n = 4) and difficulty falling asleep (n = 3) also received high mean bothersomeness (7.8 and 7.2, respectively) and severity scores (7.9 and 8.0, respectively).
Bothersomeness and Severity of Symptoms/Side
Effects at the Second Interview
As was found in the first interview, the symptoms/side effects most frequently rated (n C 5) as bothersome and Only concepts reported spontaneously, or rated for bothersomeness or severity, by at least five patients at either interview are included in the table Some differences appear in symptom/side effect reporting between Tables 1 and 2 because the units of analysis and data sources are different. The unit of analysis in Table 1 is the coded concept. Coded concepts include all symptom/side effects that were mentioned, regardless of when the patient brought them up in the interview, and cover the entire database of interview transcripts. The frequency of a coded concept thus represents the overall predominance of that concept. The unit of analysis in Table 2 is per patient. Here, the data come from interviewer notation in a table from the interview guide. At this point of the interview, symptoms that were offered by patients in response to open-ended questions were added to the table as 'spontaneous' and the interviewer then asked about symptom/side effects (from a set list) that had not been spontaneously mentioned. Positive responses to the additional symptom/side effect questions are then listed as 'probed' in the table. The results from the table are then carried over into the severity/bothersomeness rating exercise form, where they are offered back to the patient to rate. Since these data are per patient and represent only one point in time during the interview, they cannot represent the predominance of a concept severe in the second interview were given low-to-moderate scores. These were generally the same symptoms/side effects most often rated for bothersomeness and severity at the initial interview (Table 2) , with the exceptions of muscle pain/cramping and numbness/tingling, which were each rated by twice as many patients for bothersomeness and severity in the second interview. Mean bothersomeness and severity scores were notably lower (by 2.0 and 2.5 points, respectively) for tiredness at the second interview compared with at the first interview, and notably higher for diarrhea (by 2.0 and 2.1 points, respectively). The symptoms/side effects given the highest mean bothersomeness ratings in the first and second interviews are shown in Fig. 1 . As with the initial interview, a number of symptoms/ side effects at the second interview (difficulty staying asleep, reduced quality of sleep, frequent daytime urination, toe infection, vomiting, nail pain, voice changes) received high bothersomeness and severity scores (range 7.0-10), but were rated by only one or two patients. Poor appetite also received high mean bothersomeness (7.5; n = 4) and severity scores (7.3; n = 4), which were substantially higher than those scores reported for this symptom/side effect at the initial interview (5.7 and 6.3, respectively; n = 5).
When patients at the second interview were asked what their most bothersome symptom/side effect was during the trial, four symptoms/side effects (diarrhea, tiredness, muscle pain/cramping, and shortness of breath) accounted for half of the 18 answers given ( Table 3) . The remaining nine patients each quoted a different symptom/side effect as their most bothersome (three patients chose not to answer this question). Patient quotes from the second interview relating to their most bothersome symptom are shown in supplementary online material Table 2 .
Treatment Expectations, Satisfaction, and Difficulty with Symptoms/Side Effects
When asked about expectations of their treatment, patients described a physician-confirmed reduction or stabilization of tumor size, improvement in quality of life, and remaining on medication as long as possible without intolerable side effects. When describing how they defined a successful treatment, patients focused on tumor size reduction, experiencing fewer negative effects and a reduction in the impact on daily functioning. The mean treatment satisfaction score was high (9.0 out of a maximum of 10.0), and there was a low level of difficulty with symptoms/side effects (mean score of 2.0 out of a maximum of 10.0) ( Table 4) .
Discussion
Evidence suggests that direct patient reporting of some symptoms during treatment may be associated with greater sensitivity and reliability than reporting by patients to their physician [2] [3] [4] , and also provides a personal perspective from the patient that is not attainable with standard AE reporting. In this study, we used semi-structured patient interviews to elicit qualitative data on symptoms/side effects at two time points from patients with aNSCLC receiving osimertinib in a clinical trial. Our aim was to improve our knowledge of the impact of symptoms during treatment on the patient and to increase awareness of other side effects potentially associated with this drug but not reported fully by patients to clinicians.
The first interview included 23 patients and the second interview 21 patients, appropriate sample sizes for this concept elicitation research because saturation of concept was achieved-in qualitative research, sample size estimation is based on projections of the number of participants needed to reach the point in the data collection process after which no further relevant information is elicited [18] .
A greater diversity of expressed symptoms/side effects was observed in the second interview compared with the first interview. This may be due to the longer exposure to osimertinib by the time of the second interview, giving more opportunity for symptoms/side effects to be experienced, or because of changes in the disease state (particularly in the case of disease progression). Most notable changes between interviews in the frequency of reported symptoms were large decreases in the frequency of reports of itching (from 10.1 to 4.7%) and cough (from 8.3 to 4.2%). Rash and dry skin were also less frequently reported, both of which may be associated with itching.
As with many symptoms/side effects experienced during cancer treatment, symptoms such as itching and cough may be attributed to the cancer, its treatment or both. Reduced reporting of these symptoms/side effects over the course of the treatment with osimertinib could be due to reasons other than, or in addition to, reductions in the cancer. Although patients will report a mixture of disease-and drug-related effects, importantly the side effects reported in this study were in line with those reported in the AURA trial, which found that the most common all-cause side effects were diarrhea, rash, nausea and poor appetite [8] . One point to note is that because participants were enrolled in a clinical trial, they may have had less comorbidity than patients taking osimertinib in the real world. Trial inclusion and exclusion criteria ensured a controlled population, for example, excluding patients with severe or uncontrolled systemic diseases (including uncontrolled hypertension, active bleeding diatheses, or active infection, etc.). Thus, this should be taken into account when considering the wider applicability of this research.
At both interviews, the most frequently reported symptoms/side effects were also those most often rated by patients for bothersomeness and severity, and generally received mean scores in the low-to-moderate range. However, several symptoms/side effects rated by smaller numbers (four patients or fewer) and not frequently expressed in the transcript database did receive high Fig. 1 The symptoms/side effects that patients indicated were most bothersome and the maximum score for those symptoms during the first interview (top graph) (the mean bothersomeness rating given for the same symptoms/side effects in the second interview is also shown) and the second interview (bottom graph) (patients in the first interview did not rate these symptoms for bothersomeness). n number of patients, NRS numeric rating scale (on this rating scale, 0 indicated 'not at all' and 10 indicated 'extremely bothersome') bothersomeness and severity scores at the first interview (e.g., abdominal pain) and/or the second interview (e.g., frequent daytime urination). The high impact of these rarely reported symptoms indicates they are important to some patients and suggests that they should be considered for further exploration using PRO tools, as well as indicating the need to consider patient-reported measures in future clinical trials. In addition, when patients were asked at the second interview to name the most bothersome symptom they experienced overall, several symptoms/side effects were mentioned that were not frequently expressed or rated for bothersomeness or severity (e.g., frequent daytime urination, difficulty swallowing, and nausea).
The main findings of the current study are in agreement with previous reports of the bothersomeness of symptoms from patients with lung cancer across a wide spectrum of disease stages; fatigue, shortness of breath, chronic pain, cognitive impairment, anxiety, and sleep difficulties were reported by patients as symptoms significantly affecting their daily lives [19] . However, the current study has provided useful additional information and detail for the specific patient group enrolled in the AURA clinical trial. This gives valuable insight into the range of symptoms/side effects experienced (saturation of concept was reached, indicating that all the symptoms/side effects were identified) and their impact on patients, which can inform AE management and identify those symptoms/side effects that could be explored further to enhance understanding of a patient's journey through cancer treatment. These results show the importance of combining insights gained from examining the language patients' use with other measures to achieve a multi-dimensional picture of a patient's experience of a disease.
It can be difficult for patients [19] and physicians to determine conclusively whether the symptoms experienced are due to the cancer or its treatment, particularly at the very early stages of a clinical drug development program. Thus, while it is interesting to explore the potential evolution of symptoms/side effects over time (as done briefly above, by comparing reports at the first interview with those at the second interview), this study was not designed to distinguish treatment side effects from cancer-related symptoms. Rather, our aim was to ensure that all symptoms/side effects concepts expressed by patients in the osimertinib trials were elicited and recorded, regardless of what patients attributed them to. These data could help to inform the benefit-risk profile of osimertinib and identify items to be studied in future studies. They could also aid communication with patients who receive this drug, and potentially identify where additional strategies to manage symptoms and side effects are required in patients receiving osimertinib (e.g., the bothersome symptoms are those that could prompt additional palliative care).
Despite some symptoms/side effects being rated as severe and highly bothersome, a low level of difficulty in coping with side effects experienced during treatment was reported, and patients expressed a high degree of satisfaction with osimertinib therapy, supporting clinical data that indicate a manageable tolerability profile [20] . This is an important observation, since patients will naturally incorporate multiple considerations when making such assessments, including the perceived benefits of treatment with osimertinib, the impact of the symptoms/side effects on their daily lives, and a comparison of these factors with previous treatment experiences. 
Conclusion
In conclusion, the information gathered on the symptoms/ side effects experienced by patients with aNSCLC participating in a clinical trial of osimertinib enhances understanding of the patients' experience during treatment, demonstrating that it is essential to have both clinician and patient perspectives to enable the development of accurate drug benefit-risk profiles. These data could aid treatment decisions, guide the management of AEs, and improve the information given to patients receiving osimertinib, as well as informing the design of PRO tools used in future clinical trials. Further studies will focus on key items identified in this interview study, with the aim of gathering more specific qualitative data from a larger population of patients using specific PRO tools, including the PRO-CTCAE.
